Skip to Content

Oxymorphone Pregnancy and Breastfeeding Warnings

Oxymorphone is also known as: Numorphan, Numorphan HCl, Opana, Opana ER

Oxymorphone Pregnancy Warnings

This drug should be used during pregnancy only if the benefit clearly outweighs the risk to the fetus. US FDA pregnancy category: C Comments: -Prolonged use of opioids during pregnancy can result in physical dependence in the neonate; women should be advised of the risk of neonatal abstinence syndrome and ensure that appropriate treatment will be available. -Long-acting opioids should not be used during and immediately prior to labor, when short acting analgesics or other analgesic techniques are more appropriate.

Animal studies have shown that oxymorphone exposure during pregnancy is associated with reduced fetal weight. In a pre and postnatal developmental toxicity study, administration to female rats during gestation showed reduced litter size at a dose of 25 mg/kg/day (attributed to an increase in the incidence of still born pups) and an increase in neonatal death at 5 mg/kg/day or more (0.4 times a total human daily dose). Low pup birth weight, decreased post-natal weight gain, and reduced post-natal survival of pups occurred when born of dams treated with 25 mg/kg/day (about 2 times a total human dose). There are no adequate and well-controlled studies in pregnant women. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Oxymorphone Breastfeeding Warnings

Caution is advised; generally other agents are preferred over this drug during breastfeeding. Excreted into human milk: Unknown Excreted into animal milk: Data not available Comments: Breastfed infants should be closely monitored for excess sedation and respiratory depression; withdrawal symptoms can occur when maternal administration of this drug is stopped.

See references

References for pregnancy information

  1. "Product Information. Opana ER (oxymorphone)." Endo Laboratories LLC, Chadds Ford, PA.
  2. "Product Information. Opana (oxymorphone)." Endo Laboratories LLC, Chadds Ford, PA.

References for breastfeeding information

  1. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  2. "Product Information. Opana ER (oxymorphone)." Endo Laboratories LLC, Chadds Ford, PA.
  3. "Product Information. Opana (oxymorphone)." Endo Laboratories LLC, Chadds Ford, PA.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.